Rheumatoid arthritis (RA) with concomitant hepatitis B virus (HBV) infection represents a therapeutic challenge due to the risk of HBV reactivation under immunosuppressive treatment. To date there are few data concerning the HBV reactivation following treatment with abatacept coming from anecdotal case reports. This observational retrospective study was aimed to assess the safety profile of abatacept in this particular clinical setting.
Safety of abatacept in rheumatoid arthritis with serological evidence of past or present hepatitis B virus infection
PADOVAN, Melissa
Primo
;TROTTA, Francesco;GRILLI, Anastasio;GOVONI, MarcelloUltimo
2016
Abstract
Rheumatoid arthritis (RA) with concomitant hepatitis B virus (HBV) infection represents a therapeutic challenge due to the risk of HBV reactivation under immunosuppressive treatment. To date there are few data concerning the HBV reactivation following treatment with abatacept coming from anecdotal case reports. This observational retrospective study was aimed to assess the safety profile of abatacept in this particular clinical setting.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Padovan_et_al-Arthritis_Care_&_Research.pdf
accesso aperto
Descrizione: post print
Tipologia:
Post-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
658.72 kB
Formato
Adobe PDF
|
658.72 kB | Adobe PDF | Visualizza/Apri |
|
acr.22786.pdf
accesso aperto
Descrizione: versione editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
111.86 kB
Formato
Adobe PDF
|
111.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
